3.14
-0.63%
Close of 9 Nov 2026, in EUR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Evotec
Its shares trade on XETRA under the ticker EVT.DE. It has been listed since 11 October 1999. In the fiscal year to 31 December 2025, it reported revenue of €788.4m and a net loss of €103.5m. At that date it held total assets of €1.78bn and shareholders' equity of €813.7m.
Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. The company is headquartered in Hamburg, Hamburg. The firm is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 11 Oct 1999
- Employees
- 3,030
- Website
- evotec.com ↗
Leadership
Pay as last reported
- Prof. Dr. Iris LoewfriedrichIndependent Chairwoman of the Supervisory Board, since 2014€155,000
- Dr. Christian WojczewskiChief Executive Officer, Member of the Management Board€1.1m
- Mr. Roland SackersIndependent Vice Chairman of the Supervisory Board, since 2019€150,000
- Ms. Laetitia RouxelChief Financial Officer, Member of the Management Board€1.8m
- Mrs. Aurelie DalbiezChief People Officer, Member of the Management Board€469,000
- Dr. Cord DohrmannChief Scientific Officer, Member of the Management Board€1.2m
- Ms. Camilla LanguilleIndependent Member of the Supervisory Board€92,123
- Dr. Constanze Ulmer-EilfortIndependent Member of the Supervisory Board€110,000
- Dr. Duncan MchaleMember of the Supervisory Board€44,713
- Mr. Wesley WheelerMember of the Supervisory Board€44,713
- Mr. Volker BraunSenior Vice President, Head of Global Investor Relations and ESG, since 2021
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 91
- Environment
- 99
- Social
- 99
- Governance
- 76
- Direct emissions (scope 1)
- 13,756 t
- Energy emissions (scope 2)
- 21,556 t
- Value chain emissions (scope 3)
- 180,262 t
- Women in the workforce
- 54.7%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Evotec SE boasts several strengths that set the company apart:
Weaknesses
- Despite its strengths, Evotec SE also faces certain weaknesses:
Opportunities
- Evotec SE has opportunities to leverage its strengths and expand its market presence:
Threats
- Evotec SE faces certain threats that could impact its performance:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.